Navigation Links
Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
Date:10/31/2007

CRANBURY, N.J., Oct. 31 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (AMEX: PTN) announced today the initiation of dosing in a Phase 1 clinical trial of PL-3994, a long acting analog of atrial natriuretic peptide, under development for treatment of acute decompensated congestive heart failure (CHF). The trial is being conducted under an Investigational New Drug application Palatin submitted to the U.S. Food and Drug Administration. Future plans include the development of PL-3994 for long term administration in patients with chronic congestive heart failure.

The Phase 1 trial of PL-3994 is a randomized, double-blind, placebo- controlled, single-ascending dose study in healthy volunteers who will receive the drug subcutaneously. The evaluations will include safety, tolerability, pharmacokinetics and several pharmacodynamic endpoints, including endogenous messenger levels such as cyclic guanosine monophosphate.

Dr. Trevor Hallam, Palatin's Executive Vice President for Research and Development, stated, "We are excited to begin clinical trials of PL-3994, a compound developed by Palatin scientists that has the potential to become a new tool for physicians to advance the treatment of congestive heart failure. CHF is the single most common cause of hospitalization in the U.S. for patients older than 65 years of age and an underserved medical condition."

Atrial natriuretic peptide (ANP) is a naturally produced peptide hormone involved in regulation of water and sodium levels in the circulation. Palatin's PL-3994 is a peptidomimetic compound, which incorporates features of both natural ANP and small molecules.

Preclinical studies have demonstrated that PL-3994 is highly potent. Its longer duratio
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Palatin Technologies and King Pharmaceuticals Report Data Showing Improvements in Sexual Relationship and Self-Esteem in Patients with Erectile Dysfunction Treated with Bremelanotide
2. Palatin Technologies and King Pharmaceuticals Announce Plan To Present Results of Bremelanotide Phase 2b Studies in Men With Erectile Dysfunction
3. Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery of GLP-1 and PYY
4. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
5. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
6. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
7. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
8. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
9. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
10. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
11. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)... , KALAMAZOO, Mich., Dec. 3 /PRNewswire-Firs...nced today that its Board of Directors has authori...f its common stock. The manner, timing and amount...y,s management based on their evaluation of market...l be subject to regulatory considerations. Purcha...
(Date:12/3/2009)... , BEDFORD, Mass., Dec. 3 Mi...mplant systems, today announced it has been named ...rum. ,, The company was selected for pioneeri...ted, responsive implants designed to bridge the ga...CHIPS, technologies have broad applicability, from...
(Date:12/3/2009)... , MAPLE GROVE, Minn., Dec. 3 /PRNewswir...ced the next phase of its strategic plan for centr...nded release topiramate), an internally developed ...being developed with Upsher-Smith,s proprietary fo...inical trial in early 2010 for the adjunctive trea...
Breaking Medicine Technology:Stryker Announces $750 Million Share Repurchase Program and Declares a $0.15 Per Share Quarterly Dividend 2MicroCHIPS Named 2010 Technology Pioneer by World Economic Forum 2Upsher-Smith Announces Milestone in Development of CNS Strategy 2Photos 3A 2010 All New Kia Soul Awarded 2009 Top Safety Pick by Insurance Institute for Highway Safety 54439 1Photos 3A 2010 All New Kia Soul Awarded 2009 Top Safety Pick by Insurance Institute for Highway Safety 54439 2Photos 3A 2010 All New Kia Soul Awarded 2009 Top Safety Pick by Insurance Institute for Highway Safety 54439 3AVMA Unveils Improved Online Press Room to Help Journalists 54435 1AVMA Unveils Improved Online Press Room to Help Journalists 54435 2AVMA Unveils Improved Online Press Room to Help Journalists 54435 3Sun Pharmaceutical to File HSR Application for Taro Tender Offer 54431 1Sun Pharmaceutical to File HSR Application for Taro Tender Offer 54431 2Sun Pharmaceutical to File HSR Application for Taro Tender Offer 54431 3
... Jan. 10 Celltrion, Inc., a Korean,biopharmaceuti...act,manufacturing, and CSL Limited, Australia,s le...he signing of an agreement for the development,and...ibody therapy for the,treatment of acute myeloid l... are currently being conducted by CSL in Australia...
...NTREAL, Jan. 9 Pharmion,Corporation (Nasdaq: PHR...,the enrollment of the first patient in a Phase 2 ...the Companies, isotype-selective histone,deacetyla...tion with,Vidaza(R) (azacitidine for injection), P... relapsed or refractory Hodgkin lymphoma (HL) or,n...
Other Medicine Technology:Celltrion and CSL Announce Collaboration to Develop and Manufacture Monoclonal Antibody 2Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma 2Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma 3Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma 4Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma 5Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma 6Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma 7
(Date:12/3/2009)...SNewswire/ -- The American Association of Homes an...te for passing Sen. Michael Bennet,s (D-Colo.) ame...anteed benefits, and strengthens Medicare by keepi...ver tsunami of retiring baby boomers fast approach...tion currently before Congress to address Medicare...
(Date:12/3/2009)...reas, but each patient will be different, experts ...) -- A class of drugs still taken by millions of ...igher risk of dying and heart failure than the new...lfonylureas, long a mainstay of diabetes treatment... oral anti-diabetes drugs, but doctors said the fi...
(Date:12/3/2009)...ing of diabetes, cardiovascular disease, researche...ews) -- Pregnant women who develop gestational glu...isk for metabolic syndrome three months after they...ucose intolerance is less severe than gestational ... factors (including high blood pressure, obesity a...
(Date:12/3/2009)...f screening test, researcher says, , ,...h points to the possibility of a genetic link betw...high blood pressure who had a gene variant that re...to be twice as likely as those without the variant.... , The finding may lead to a way to identify p...
(Date:12/3/2009)... -- Chiltern International Limited (Chiltern), a g...ng clinical development and staffing services in E...appointment of Dr. Sharon Moore as Executive Vic... Dr. Moore is based at Chiltern,s Bristol, Tenness...h 15 years of industry experience. Prior to joinin...
Breaking Medicine News(10 mins):Health News:Diabetes Drugs Go Head-to-Head in Study 2Health News:Diabetes Drugs Go Head-to-Head in Study 3Health News:Blood Sugar Intolerance May Predict Postpartum Ills 2Health News:Vitamin D May Be Tied to Heart Disease Via Genes 2Health News:Chiltern Names Dr. Sharon Moore as Executive VP, Global Quality & Medical Affairs 2
...cation of modulated radiotherapy in the treatment ...y means of other conventional therapies. The techn...ost adapted to the tumoral volume and risk areas, ...total dose equivalent to conventional ones. In thi...
...it comes to injury-related deaths, the gap between...ording to a study by researchers at the Johns Hopk...ound that between 1999 and 2005 injury-related dea... Injury Prevention . , "Between the years of 199...
...rnational Living Ultimate Event, held recently in ...most from the U.S. and Canada - who are, looking t...ing for better access to quality health car... their,homework so they don,t make mistakes. That ...
...NIO, June 16 BME (BioMedical Enterprises,Inc.), a...in orthopaedic,shape memory implant technology, to...) (BOSS), a nitinol implant designed for internal ...OSS nitinol,staple changes shape when heated above...
...ship Provides the Medical Device Industry with Bes...utions, PRINCETON JUNCTION, N.J., June 16 R-Squa...nd solutions, announced a,multi-year partnership w... including manufacturers of medical,devices and di...
...CLE #1 FOR IMMEDIATE RELEASE , Coffee,s aroma ki...ural and Food Chemistry , Drink coffee to send a..., warm aroma? An international group of scientists...ats, they found that coffee aroma orchestrates the...
Other Medicine News:Health News:Modulated radiotherapy can cut treatment time for cancer of the rectum without increasing toxicity 2Health News:Racial disparities reduced in injury related mortality 2Health News:International Living Ultimate Event Attracts Nearly 300 Attendees Who Explore the Growing Trend of Retiring Overseas 2Health News:International Living Ultimate Event Attracts Nearly 300 Attendees Who Explore the Growing Trend of Retiring Overseas 3Health News:BME (BioMedical Enterprises, Inc.) Announces U.S. Launch of the Barbed OSStaple(TM) (BOSS) Nitinol Implant 2Health News:R-Squared and MDMA Announce Partnership 2Health News:American Chemical Society's Weekly PressPac: June 11, 2008 2Health News:American Chemical Society's Weekly PressPac: June 11, 2008 3Health News:American Chemical Society's Weekly PressPac: June 11, 2008 4Health News:American Chemical Society's Weekly PressPac: June 11, 2008 5Health News:American Chemical Society's Weekly PressPac: June 11, 2008 6Health News:American Chemical Society's Weekly PressPac: June 11, 2008 7Health News:American Chemical Society's Weekly PressPac: June 11, 2008 8
...ence laboratory and a worldwide leader in innovati...s an extensive test menu of highly complex and uni...gy. Owned by the University of Utah, ARUP Laborato...'s university teaching hospitals and children's ho...
...ence laboratory and a worldwide leader in innovati...s an extensive test menu of highly complex and uni...gy. Owned by the University of Utah, ARUP Laborato...'s university teaching hospitals and children's ho...
...ence laboratory and a worldwide leader in innovati...s an extensive test menu of highly complex and uni...gy. Owned by the University of Utah, ARUP Laborato...'s university teaching hospitals and children's ho...
...ence laboratory and a worldwide leader in innovati...s an extensive test menu of highly complex and uni...gy. Owned by the University of Utah, ARUP Laborato...'s university teaching hospitals and children's ho...
Medicine Products: